Need more? Try out  Advanced Search (20+ criteria)»


Last Update

This profile was last updated on 12/16/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Peter Mueller?

Peter R. Mueller

Chief Scientific Officer

Vertex Pharmaceuticals Incorporated

HQ Phone:  (617) 341-6100

Direct Phone: (617) ***-****direct phone

Email: p***@***.com


+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.


  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Vertex Pharmaceuticals Incorporated

50 Northern Avenue

Boston, Massachusetts,02210

United States

Company Description

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more t...more

Background Information

Employment History

President of Research and Development and CSO

Axcella Health Inc


Epicenter Consulting LLC

Chief Scientific Officer

Pronutria Biosciences Inc

Senior Vice President, Research and Development

Boehringer Ingelheim Pharmaceuticals , Inc.


USA India Chamber of commerce

Advisory Board Member

Inhibikase Therapeutics Inc

Board Member

Gesellschaft Deutscher Chemiker


Phacilitate Limited

Advisory Board Member

Keystone Symposia

Scientific Advisory Board Member

Biosensor Forum

Advisory Board Member

GDS International Ltd


Albert Einstein University of Ulm , Germany

Faculty Member

American Association for the Advancement of Science


Royal Society of Chemistry


The RNA Society


Govenor Roland

Member of Council On Economic Competitiveness and Technology for the State of Connecticut






University of Mainz



Albert Einstein University of Ulm , Germany

undergraduate degree

Albert Einstein University of Ulm , Germany

Web References(151 Total References)

USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships [cached]

Dr. Peter Mueller
President R&D and CSO

Board of Directors | Inhibikase Therapeutics, Inc. [cached]

Peter Mueller, PhD.
Dr. Mueller joined Vertex in July 2003. As Executive Vice President Global Research and Development & Chief Scientific Officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations as well as Clinical and Non-Clinical Development, Regulatory, Patient Safety and Medical Affairs. Key areas of Vertex' R&D are Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases which led in 2011 to the successful approval and launch of INCIVEK (HepC), a NDA/MAA submission for KALYDECO (CF) with the first approval in the US in January 2012 and several proof of clinical concept candidates in various disease areas. Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide. Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.

Health Industry Updates [cached]

Vertex Pharmaceuticals Incorporated announced that Peter Mueller will retire as Executive Vice President of Global Research and Development and Chief Scientific Officer, effective October 31, 2014.

11th Winter Conference [cached]

Dr. Peter Mueller
CSO & Executive VP, Global Research & Development, Vertex Pharmaceuticals, USA "Imagine: Pharma Be Fractal"

May, 2017 | Comienzos - Part 2 [cached]

An interview with Dr Chhatwal'These research are an important part of our ongoing efforts to strengthen our leadership position in hepatitis C by developing all-oral regimens that could additional enhance the future treatment of this disease,' stated Peter Mueller, Ph.D., Executive Vice President, Global Development and Research, and Chief Scientific Officer for Vertex. 'The research of ALS-2200 and ALS-2158 announced today are created to generate data that may provide the chance to rapidly progress into Phase 2 advancement where we could evaluate several nucleotide-based regimens beginning in the next half of next yr, including regimens with INCIVEK or VX-222.'..

Similar Profiles


Browse ZoomInfo's Business
Contact Directory by City


Browse ZoomInfo's
Business People Directory


Browse ZoomInfo's
Advanced Company Directory